Insider Transactions in Q1 2022 at Epizyme, Inc. (EPZM)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2022
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,043
+23.22%
|
$13,043
$1.15 P/Share
|
|
Mar 31
2022
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,653
+9.39%
|
$20,653
$1.15 P/Share
|
|
Mar 31
2022
|
Beveridge, Roy A Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,413
+28.87%
|
$11,413
$1.15 P/Share
|
|
Feb 28
2022
|
Shefali Agarwal |
BUY
Grant, award, or other acquisition
|
Direct |
2,331
+1.45%
|
$2,331
$1.27 P/Share
|
|
Feb 28
2022
|
Joseph Beaulieu Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,331
+7.0%
|
$2,331
$1.27 P/Share
|
|
Feb 07
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
1,058
-0.67%
|
$1,058
$1.5 P/Share
|
|
Feb 07
2022
|
Joseph Beaulieu Officer |
SELL
Open market or private sale
|
Direct |
222
-0.77%
|
$222
$1.5 P/Share
|
|
Feb 02
2022
|
Joseph Beaulieu Officer |
SELL
Open market or private sale
|
Direct |
687
-2.33%
|
$687
$1.37 P/Share
|
|
Feb 02
2022
|
Jeffery Kutok Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,556
-2.56%
|
$2,556
$1.37 P/Share
|
|
Feb 02
2022
|
Grant C. Bogle President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+32.34%
|
-
|
|
Feb 02
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
2,639
-1.65%
|
$2,639
$1.37 P/Share
|
|
Jan 31
2022
|
Legorreta Pablo G. Director |
BUY
Open market or private purchase
|
Indirect |
22,666,667
+41.59%
|
$22,666,667
$1.5 P/Share
|
|
Jan 26
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
2,922
-1.79%
|
$5,844
$2.02 P/Share
|